it's interesting in that the way he clearly ranked the CRC trial ahead of the inflammation trial - and mentioned the CRC trial being linked to a partnership. I was wondering if the plan is to get a partner to fund the CRC trial - the news of that trial with a viable partner would clearly raise the SP materially. Maybe at that point, it creates a more attractive window for a raise to support the HIV / inflammation trial. I have no idea, but that was my initial reaction, and that could work well.